Angeliq vs Bijuva: 12 Key Differences Compared (2026)

Independent editorial research. Educational only — not medical advice, and not reviewed by a clinician. Medical review policy · Affiliate disclosure — this page contains sponsored links.

Angeliq vs Bijuva has no universal winner. Both are FDA-approved daily pills for women with a uterus. Bijuva pairs estradiol with progesterone and is taken each evening with food. Angeliq pairs estradiol with drospirenone, can be taken any time with or without food, and adds kidney, liver, adrenal, and potassium screening. As of July 2026, Bijuva's label carries no boxed warning. Angeliq's still does.

That last sentence surprises almost everyone. Including, it turns out, Bijuva's own website — which is still showing women a warning the FDA removed months ago.

→ See all 12 verified differences

Which one should you ask about?

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

Is there a head-to-head Angeliq vs Bijuva trial?

Here's the admission that shapes this entire page.

We searched for a head-to-head trial and didn't find one. Not in the labels, not in the medical literature databases, not in the trial registry. If one exists somewhere we couldn't reach, we'd want to know.

So nobody — not us, not either manufacturer, not the database page sitting at the top of these search results — can tell you which one works better for hot flashes. If you came here hoping we'd hand you a winner, we don't have one, and we're not going to invent one to make this page feel more satisfying.

If a head-to-head verdict is genuinely what you need, the person best placed to weigh the two for your body is a menopause-trained clinician looking at your history.

But here's why that missing trial is good news for you.

When there's no overall winner, the fit differences become the entire decision. And those differences aren't hidden. They're printed, in public, in two FDA documents that almost nobody bothers to read side by side.

We read both. That's what the rest of this page is.

Before you go further

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

Angeliq vs Bijuva: what is the main difference?

Let's define the words first, because they get used sloppily everywhere else.

• Estradiolis the main estrogen your ovaries made before menopause. Both pills use it. It's the part that treats hot flashes.
• Progestogen is the umbrella word for the second hormone. For a woman with a uterus using systemic estrogen, a progestogen is generally added to reduce the risk of the uterine lining thickening and of endometrial cancer. Which product and which regimen remain prescriber decisions.
• Progesteroneis the progestogen in Bijuva. It is chemically identical to the progesterone your body makes. The progesterone in the capsule is manufactured and micronized — ground fine so the body can absorb it.
• Progestin is a lab-made compound that acts like progesterone but has a different chemical structure. Drospirenone is a progestin. Angeliq uses it.

That's the fork in the road.

The 12 differences, verified

Labels checked on DailyMed (NLM's official label database) on 27 July 2026. Each row carries a status tag so you can see how solid it is.

Status key: LABEL = printed in the current FDA-approved label · FDA = FDA database or announcement · PRICE = dated pricing snapshot, changes often

Which one works better for hot flashes?

Here's what each label reports.

Bijuva. In a 12-week substudy inside a 52-week safety trial, women started with about 72 moderate-to-severe hot flashes per week. By week 12, the 1 mg/100 mg group was down about 55 per week and the 0.5 mg/100 mg group about 54, against about 40 for placebo. Both doses beat placebo with a p-value below 0.001.

Angeliq.In a placebo-controlled trial of the 0.25 mg/0.5 mg strength, women started with about 10.7 hot flashes per day. By week 12 they were down 7.71 per day, against 4.54 for placebo — a difference of about 3 fewer hot flashes a day.

The thing about Angeliq's higher strength

Angeliq's 0.25 mg/0.5 mg strength has its own dedicated hot-flash trial, described above. The higher 0.5 mg/1 mg strength got its hot-flash support a different way — through a bioequivalence study showing its estradiol behaves in the body the same way as an already-approved 1 mg estradiol tablet.

That's a legitimate regulatory path, not a scandal. But it means the two strengths have different kinds of evidence behind them, and if your prescriber is choosing between them, it's worth knowing.

One line in Bijuva's label almost nobody reports

We're including this because it's printed in the FDA-approved label, and leaving it out would be the kind of omission we criticize other pages for.

About 31% of the women in Bijuva's trial identified as Black or African American. After adjusting for body weight, smoking, alcohol, and starting estrogen levels, the label states that Bijuva did not show statistically significant reductions in both hot-flash frequency and severity by week 12 in that group.

Read that carefully, because it's easy to misread.

This is an adjusted subgroup analysis. Subgroups are smaller than the full trial, which makes them much less able to detect a real effect even when one exists. This is not evidence that Bijuva doesn't work for Black women.It is a line in an FDA label that raises a question the trial wasn't designed to answer.

It's also exactly the kind of thing to bring to an appointment: “I read that the Bijuva trial didn't show a clear result in Black women after adjustment. Does that change what you'd recommend for me?”A good clinician will have a thoughtful answer. You shouldn't have to dig through a PDF to find that question.

Why does Bijuva's website show a warning the FDA removed?

This is the finding that made us build this page.

The label currency audit

The first six products to get FDA-approved label changes were Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva.

What actually happened, briefly

In November 2025, after an expert review, the FDA asked drug companies to rewrite the warnings on menopausal hormone products. The agency's position was that the old boxed warning — built largely on a trial whose average participant was 63 years old — was scaring off women in their early fifties, for whom the risk picture looks different.

The FDA approved the first batch of six updated labels on 12 February 2026. Bijuva was one. Angeliq wasn't. The agency has said 29 manufacturers submitted proposed updates.

The FDA is implementing the change product by product, through individual labeling approvals.That's why two pills in the same pharmacy drawer can carry different warnings right now. It's a queue, not a verdict.

For the fuller story, see what the FDA's warning change actually means.

The part that will annoy you

On 27 July 2026 we checked bijuva.com and its cost page. Both still displayed the full heading “WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER.” Both still labelled the prescribing-information link “Full Prescribing Information, Including BOXED WARNING.” The homepage still cited a November 2023 package insert. The pages carried the material code PM-US-BJVA-0070, dated 04/2026.

And on the cost page — on the very same screen as that warning — sits a link to the FDA press release announcing that those warnings were removed.

We're not saying the mismatch is deliberate. But if you've been sitting with a knot in your stomach after reading that page, now you know why: you were reading a warning that is no longer on the drug's label.

Now the part that matters most

And the warning timing alone does not show that Angeliq is more dangerous. Its label is simply older. If the FDA later approves revised Angeliq labeling, the presentation may change without any new head-to-head evidence existing.

Anyone using “Bijuva's warning was removed” as a reason to pick Bijuva is reading a filing queue as if it were a safety study.

Your patient handout may still sound different

Bijuva's FDA patient information still includes lowest-dose language and still lists dementia among possible serious effects, even though the professional label no longer carries a boxed warning. The exact document your pharmacy hands you may vary.

So you may fill a prescription for a drug with no boxed warning and walk out holding a leaflet that reads like there is one. That isn't a pharmacy error. It's two documents on two different update schedules.

Progesterone or drospirenone — which second hormone is better?

Before the numbers, one caveat that changes how you should read all of them: these studies compare progesterone against synthetic progestogens pooled together. They do not isolate drospirenone, they do not compare Angeliq with Bijuva, and they cannot predict an individual result.

The case for progesterone

The biggest dataset is E3N, a French cohort that followed more than 54,000 postmenopausal women. In that study, the grouped estrogen-plus-synthetic-progestogen category had a breast-cancer relative risk of 1.4, while the estrogen-plus-micronized-progesterone category had a relative risk of 0.9 — statistically indistinguishable from not taking hormones. The difference between the two categories was strongly significant.

A later systematic review pooling several studies reported a relative risk of 0.67 for progesterone compared with synthetic progestins — roughly a third lower. That review was built on a small set of observational studies, not randomized comparisons.

A joint statement from the British, International, European, Royal College and Australasian menopause societies notes that micronized progesterone and dydrogesterone are unlikely to increase venous-thrombosis risk compared with other progestogens.

The case that cuts the other way

Same research programme, different organ. That literature also raises the possibility that micronized progesterone protects the uterine lining less effectively than synthetic progestins over roughly five years of use.

That's not a footnote — protecting the lining is the second hormone's whole job.

It's also not a finding that Bijuva failed its own endometrial testing. In Bijuva's 52-week trial, endometrial biopsies found one case of hyperplasia in each active-dose group— 1 in 303 on the lower dose, 1 in 281 on the higher — and no cases of endometrial cancer.

So the honest picture is: solid one-year data for the approved regimen, and an unresolved longer-term comparative question that a randomized trial has not yet answered.

The caveat that has to be printed

E3N is an observational cohort, not a randomized trial. Women in France prescribed progesterone differed from women prescribed synthetic progestins in ways researchers can adjust for but never fully eliminate. It's strong, suggestive evidence. It isn't proof.

The ongoing PROBES trial in Sweden compares 100 mg micronized progesterone against 0.5 mg norethisterone acetate, each with 1 mg oral estradiol. It may clarify progesterone against one synthetic progestogen. It does not test drospirenone, and it is not an Angeliq-versus-Bijuva trial.

What “bioidentical” actually means here

You'll see Bijuva described as bioidentical. That's accurate — its hormones are chemically identical to the ones your body makes. It is not, by itself, a safety claim. And you don't have to take our word for it. Here is the footnote printed on Bijuva's own homepage, from the manufacturer:

“There are no data that suggest that bioidentical hormones are superior to synthetic hormones.”

That's Mayne Pharma. On their own marketing site. About their own product.

One more thing, because this trips people up constantly. Bijuva being “bioidentical” has nothing to do with compounded bioidentical hormones. Bijuva is an FDA-approved finished drug, made to a fixed formula and reviewed before marketing. Compounded hormone products may be prepared by a compounding pharmacy or an outsourcing facility and are not FDA-approved for safety, effectiveness, or quality in the same way. Separate categories. We never treat them as equivalent.

Angeliq's own argument, which usually goes unmentioned

Drospirenone isn't just “the synthetic one.” It blocks aldosterone, the hormone that tells your body to hold onto salt and water.

In randomized trials of postmenopausal women with high blood pressure, drospirenone-plus-estradiol regimens lowered blood pressure — including on top of an ACE inhibitor — while estradiol alone performed like placebo. Those trials generally used 2 to 3 mg of drospirenone. US Angeliq contains 0.25 mg or 0.5 mg. One dose-ranging study did not find a significant 24-hour systolic reduction at 1 mg, which is still double the highest US Angeliq dose.

So the honest sentence is this: the blood-pressure evidence for drospirenone is real, and it was generated well above the doses sold in the United States. It does not establish a blood-pressure benefit for US Angeliq. Worth raising with a prescriber. Not worth promising yourself.

Why we're not sending you to a compounding pharmacy

Two providers we partner with — Winona and Inner Balance — build their offering around compounded hormones. We're not featuring them here, and we'd rather say why out loud than quietly leave them off.

This page is about two FDA-approved brand-name products. A compounded preparation isn't a version of either one. It's a different regulatory category with a different evidence base. Recommending one here would blur a line we've decided not to blur, whatever it costs us.

Who should not take Angeliq, and who should not take Bijuva?

Read this section slowly.

Why drospirenone brings kidneys into it

Drospirenone blocks aldosterone. Aldosterone tells your kidneys to hold sodium and clear potassium. Block it, and potassium can rise. High potassium can affect heart rhythm, which is why the label draws a hard line at kidney impairment, liver impairment, and adrenal insufficiency.

The label's own numbers: in a study using 1 mg estradiol with 3 mg drospirenone, potassium reached 5.5 mEq/L or higher in 8 of 112 women (7.3%) compared with 3 of 118 (2.6%)on placebo. There was one reading above 6 mEq/L and one low-sodium reading — both after five days of ibuprofen.

The everyday medicines that belong on your list

Angeliq's label calls for caution, and possibly potassium monitoring, in women taking medicines that raise potassium. The list includes things you might not think of:

• NSAIDs — including over-the-counter ibuprofen and naproxen
• Potassium-sparing water pills
• Potassium supplements
• ACE inhibitors (drug names usually ending in -pril, like lisinopril)
• ARBs (usually ending in -sartan, like losartan)
• Heparin
• Aldosterone blockers such as spironolactone

Regular NSAID use belongs on the medication list you hand your prescriber. The label calls for caution and possible monitoring — it does not tell every woman who occasionally takes ibuprofen to stop.

The other things both labels flag

Both labels tell you to discuss or monitor: gallbladder disease, migraine, thyroid medication (estrogen can change how much thyroid hormone you need), high triglycerides, high blood calcium, hereditary swelling of the face or tongue, asthma, diabetes, epilepsy, and lupus. Neither product is automatically off-limits for these. They belong in the conversation.

Which one is easier to actually take every day?

Most pages treat this as a throwaway line. It's probably the most practical difference between the two.

What food actually does to Bijuva

The label reports it plainly. With a high-fat meal compared to an empty stomach:

• Progesterone peak level rose 162%. Total exposure rose 79%. Time to peak shifted from 2 hours to 3.
• Estradiol peak level dropped about 54%, and time to peak stretched from 1 hour to 12 hours.
• Estradiol total exposure was not affected by food.

That last line matters. Food doesn't reduce how much estradiol you absorb overall — it flattens and delays the peak. For progesterone, food genuinely increases exposure.

Take Bijuva on an empty stomach and you're not taking a weaker dose. You're producing a different absorption pattern than the one the label was written around. That's why “with food” is part of the prescribed regimen rather than a lifestyle tip.

The honest routine question

Ask yourself one thing: can you reliably eat something in the evening and take a capsule right after, most nights, for months?

If yes, Bijuva's routine is fine and the food rule is just a habit.

If your evenings are chaotic, if you work nights, if you skip dinner regularly, or if you already know you're the kind of person who remembers pills at 6am and never at 9pm — Angeliq's flexibility is a real advantage, and a legitimate thing to say out loud at your appointment. Adherence isn't a character flaw. A medicine you actually take beats a theoretically better one you don't.

If you miss a dose

Follow the instructions in the leaflet for the product you're holding — the two are worded differently, and we're not going to invent a rule that covers both. Your pharmacist can answer this in thirty seconds at no cost.

Which one helps vaginal dryness and painful sex?

If hot flashes are wrecking your sleep andvaginal tissue changes are causing discomfort, the higher-strength Angeliq carries both indications. Whether that makes it right for you is a clinician decision — but it's a real difference between the two products and it belongs in your conversation.

If vaginal atrophy is your onlyproblem — no hot flashes, no night sweats — then whole-body hormone therapy may be more medicine than the situation calls for. Low-dose vaginal estrogen delivers a small amount of estrogen directly where the problem is.

That's not us talking you out of anything. It's Angeliq's own label telling your prescriber to consider the local option first. If that describes you, this isn't your page. Read our guide to vaginal estrogen instead, and come back if hot flashes join the party later.

What side effects are listed for Angeliq and Bijuva?

Angeliq's label notes that common side effects were generally more frequent at the 1 mg estradiol strength than at 0.5 mg— useful if you and your prescriber are weighing starting low.

Bijuva's label reports breast tenderness in 4.0% at the lower dose versus 10.4% at the higher dose, against 0.7% on placebo. Same pattern: higher estradiol, more breast tenderness.

Weight increase and fluid retention both appear in Bijuva's post-approval reporting.That's the concern women raise most often, and it's honest to say the label acknowledges it — while noting post-approval reports come from an unknown number of users and can't establish how often it happens or whether the drug caused it.

What do women actually say about each one?

On Drugs.com, Angeliq averages 7.9 out of 10 across 54 ratings, with 74% reporting a positive effect. Bijuva averages 6.0 out of 10 across 54 ratings, with 42% positive. These are small, self-selected, unverified samples. They are not evidence that either drug works better.

Two things before you read a single review. The samples are tiny— about 54 ratings each is a book club, not a study. And reviewers self-select: people who had a dramatic experience, wonderful or awful, write reviews. People for whom it quietly worked mostly don't.

Three real quotes, each from a different review page, each about a different friction point. We chose these deliberately — not the glowing ones — because the hard parts are what you need to plan for.

“The cost is high in the USA: $195 per month” — Angeliq reviewer, Drugs.com

“Right away I noted stomach bloating but decided to stick it out” — Bijuva reviewer, Drugs.com

“after about 4 days I started to get spotting” — Bijuva reviewer, Drugs.com

These are individual, self-reported experiences. They don't prove the medication caused the result, they aren't typical, and they're not evidence about safety or effectiveness.

How much do Angeliq and Bijuva cost in 2026?

Prices retrieved 27 July 2026. Per-day figures calculated from pack sizes (Bijuva: 30 capsules; Angeliq: 28 tablets).

The sentence to say at the pharmacy counter

Look at the Bijuva row again. $85 on one free discount card. $240.92 on another. Same drug, same day.

That's not a typo. Discount card companies negotiate separately with pharmacy chains, and neither is obliged to mention the other exists.

“Can you run this against GoodRx and SingleCare and tell me which one comes out lower?”

About the savings card

Bijuva's current copay card is limited to eligible commercially insured patients. It excludes cash-paying patients and people enrolled in Medicare, Medicaid, Medicare Advantage, Part D, Medigap, TRICARE, VHA, DOD, IHS, and other listed government-funded programs. Out-of-pocket cost varies, maximum limits apply, and the current offer expires 31 December 2026.

Download the card from the manufacturer's site and read the terms yourself. Third-party pages quote dollar figures that go stale. Given how many women reading this are over 60, that government-program exclusion is not a footnote. It may be the single biggest cost fact on the page for you.

The route this comparison hides

A clinician may instead prescribe separate FDA-approved estradiol and micronized progesterone products. That is a two-prescription regimen, not a generic substitution for Bijuva, and the clinician decides the doses, route, timing, and follow-up. But both components are available as inexpensive generics, and for many women the combined monthly cost is a fraction of a brand-name capsule.

There is also a generic one-pill combination — estradiol with norethindrone acetate, the generic of Activella. In the same GoodRx session it showed as low as $21.00 against a retail price near $124.79.

• Separate pillsmeans two prescriptions, two co-pays, two refill dates, no fixed-dose convenience. Some women hate that. Some don't care.
• The generic combination pilluses norethindrone acetate, which is a synthetic progestin. On the progesterone-versus-progestin question above, that route sits closer to Angeliq's category than Bijuva's. If micronized progesterone specifically is what you want, this is not the same thing.

Is there a generic version of either one?

FDA approval is not the same as a product on a shelf.For Bijuva, the reason is public and specific. TherapeuticsMD sued Amneal over Bijuva's patents; the case settled with Amneal receiving a licence to sell its generic starting 25 May 2032, or earlier under circumstances customary in such settlements. The last Bijuva patent listed in the FDA's Orange Book expires 21 November 2032.

So if you're waiting for a cheap generic Bijuva: it exists, it's approved, and under the current settlement it isn't coming for years.

For Angeliq, the Novast approval covers only the 0.5 mg/1 mg strength. The lower 0.25 mg/0.5 mg strength was not identified in that application. Whether it has actually launched, we can't confirm — and neither can the pages telling you it has.

Two databases, same website, opposite answers

Drugs.com's generic-availability page for Bijuva, updated 11 June 2026, states that the FDA has notapproved a generic version. Drugs.com's own 2022 generic-approvals archive, on the same website, lists the Amneal approval. Same site. Opposite answers. A woman reading only the first page walks away with the wrong information.

How to check this yourself

Use Drugs@FDA or the Orange Book, both free on fda.gov. Search by product name, strength, dosage form, and manufacturer. Do not use an NDC number to confirm that a drug is FDA-approved — having one does not establish approval, and the FDA has said presenting it that way is misleading.

Does insurance cover Angeliq or Bijuva?

Here's what to check before your first fill, in order:

1. Look up the drug on your plan's formulary. Every commercial plan and Medicare Part D plan publishes one, usually searchable by drug name. Note the tier.
2. Check for prior authorization. This means the plan wants your prescriber to justify the choice before it pays. It's routine, not a rejection.
3. Check for step therapy. This means the plan wants you to try something cheaper first. Also routine, and often appealable if there's a clinical reason.
4. Check quantity limits and whether the plan requires mail order or a preferred pharmacy for a 90-day fill.
5. Ask whether a formulary exception applies. Requesting one is a normal process. Your prescriber's office does it regularly.
6. If you're on Medicare or Medicaid, remember the manufacturer copay card is not available to you.

For more on this topic, see our page on does insurance cover Angeliq.

Can you switch from Angeliq to Bijuva, or the other way?

Things we won't give you, and neither should anyone else:

• A dose conversion ratio between the two
• A “finish this pack, start that one Monday” schedule
• A washout period
• Advice to split, combine, or substitute capsules and tablets
• Any suggestion that matching the estradiol milligrams makes them equivalent

Switching changes the progestogen — and may also change the estradiol dose, the dosage form, the food timing, the inactive ingredients, and the absorption pattern. That's more than one variable.

The bleeding numbers, done properly

Angeliq's label reports that at one year, roughly 15% of women on the lower strength and 22% on the higher strength had any bleeding or spotting. Bijuva's label reports that at 52 weeks, 67.6% of women on the lower dose and 56.1% on the higher dose had no bleeding at all— against 78.9% on placebo.

Those numbers cannot be subtracted from each other.One counts women who bled. The other counts women who didn't. Different trials, different definitions, different populations. Turning them into “Angeliq causes less bleeding” is a mistake, and we've watched it happen.

What both labels support is simpler: bleeding or spotting can occur with either product. Persistent, recurrent, or otherwise concerning postmenopausal bleeding needs evaluation — not a wait-and-see rule from a website.

The timing trap when you switch

Moving from Angeliq to Bijuva changes the schedule. Angeliq is whenever you like. Bijuva is evening, with food, and the food part matters for the reasons above. Set a phone alarm for after dinner on day one.

If you're switching because of a side effect

Before switching, it's worth working out whether the problem is the estrogen or the second hormone — because a brand switch changes several things at once. Our guide on signs your HRT dose is too low walks through how to tell the difference.

What if your pharmacy can't get it?

We did not conduct a pharmacy stocking survey, so we can't tell you how often either product is kept on hand. Both are brand-name products without a purchasable generic, and neither appears on the FDA's drug shortage list. If a pharmacy says it can't get one, the useful next step is to ask what they've actually checked.

“Can you check whether your wholesaler has it, and how long a special order would take for this exact strength?”

That turns “we don't have it” into “here's when we could.” If your usual pharmacy can't help, an independent pharmacy or mail order is worth trying — remember the $50 Bijuva mail-order price in the cost table. The cheapest option we found and the one most likely to have it were the same option.

How did The HRT Index verify this comparison?

Sources accessed and checked 27 July 2026

• Bijuva's current FDA-approved label on DailyMed (set ID bc52489a-5149-411d-9665-2c75405ad15d, revised April 2026) — indications, dosing, food-effect data, contraindications, inactive ingredients, trial results, adverse reactions, and the absence of a boxed warning
• Angeliq's current label on DailyMed (set ID 761834c2-6b61-4583-84c2-f1ca4a97c4f2, revised December 2023) — indications, dosing, contraindications, potassium data, trial results, adverse reactions, and the boxed warning still in place
• bijuva.com and its cost page as displayed to the public, including material code PM-US-BJVA-0070 dated 04/2026
• The current Bijuva copay card terms, including eligibility exclusions and the 31 December 2026 expiration
• GoodRx pricing pages for both products, in one session
• FDA's first-generic approval records for Amneal's estradiol/progesterone generic (May 2022) and Novast's drospirenone/estradiol generic (October 2025)
• The public patent-settlement announcement establishing the May 2032 licensed entry date for the Bijuva generic
• Drugs.com's comparison page, its generic-availability pages, and its user-rating aggregates

Cited to named published sources, not independently reproduced

• The E3N cohort breast-cancer figures and the pooled systematic review
• The drospirenone blood-pressure trials and their doses
• The PROBES trial protocol
• The joint statement of the British, International, European, Royal College and Australasian menopause societies

Checked but not confirmed — flagged rather than glossed over

• Whether Bayer currently offers a commercial copay card for Angeliq
• Whether either approved generic has actually launched commercially
• How consistently pharmacies stock either product
• Whether any named telehealth provider will prescribe either specific brand

What we did not do, and won't claim

• We did not test either medication
• We did not survey pharmacies
• We are not clinicians, and this page was not reviewed by one — see our medical review policy
• We have no financial relationship with Bayer or Mayne Pharma and earn nothing on either drug

What goes stale, and when we re-check

What to ask before you fill either prescription

Three questions settle this in about two minutes of appointment time. Bring the information that lets your clinician answer them.

Also bring: recent blood pressure readings, your bleeding history, any ingredient concerns (lactose, gelatin, soy), and an honest answer about whether you can take a capsule with an evening meal most nights.

What a good answer sounds like:specific to you, willing to explain the trade-off, comfortable saying “let's start here and reassess in three months.”

What a brush-off sounds like:“they're basically the same thing,” or “don't worry about the warning,” or any version of not answering the question you asked. You are allowed to ask again.

Angeliq vs Bijuva: frequently asked questions

Is Angeliq the same as Bijuva?

No. Both contain estradiol, but Angeliq's second hormone is drospirenone, a synthetic progestin, and Bijuva's is progesterone. Their strengths, food instructions, approved uses, screening requirements, and prices all differ.

Which one contains progesterone chemically identical to the body's own?

Bijuva. Angeliq contains drospirenone, a lab-made progestin with a different chemical structure.

Is drospirenone the same as spironolactone?

No, but they're related. Drospirenone comes from the same chemical family and shares spironolactone's ability to block aldosterone. That's why Angeliq can raise potassium and why kidney and adrenal function matter with it.

Does Bijuva have to be taken with food?

Yes. The label says one capsule every evening with food. Food raises progesterone peak level by 162% and total exposure by 79%. For estradiol, food lowers the peak by about 54% and delays it, but does not change total exposure.

Can Angeliq be taken without food?

Yes. The label allows dosing with or without food, at the same time each day.

Does Angeliq raise potassium?

It can in susceptible women. It is contraindicated in kidney impairment, liver impairment or disease, and adrenal insufficiency. Medicines that raise potassium — including NSAIDs, ACE inhibitors, ARBs, potassium-sparing diuretics, potassium supplements, heparin, and aldosterone blockers — call for prescriber review and possibly potassium monitoring, not automatic exclusion.

Is Bijuva safer now that the boxed warning is gone?

No. That's a label-update timing difference, not a safety finding. Cardiovascular and breast-cancer risk information remains in Bijuva's Warnings and Precautions section. Angeliq's label simply hasn't been revised yet.

Does “bioidentical” mean safer?

No. It means the hormone is chemically identical to the one your body makes. Bijuva's own manufacturer states on its website that no data suggest bioidentical hormones are superior to synthetic ones.

Are either of these compounded?

No. Both are FDA-approved finished drugs — a different category from compounded hormone products, which may be prepared by a compounding pharmacy or outsourcing facility and are not FDA-approved for safety, effectiveness, or quality in the same way.

Which one is approved for vaginal dryness?

Angeliq's 0.5 mg/1 mg strength has an FDA indication for moderate-to-severe symptoms of vulvar and vaginal atrophy. Bijuva does not. Angeliq's own label says to consider a topical vaginal product first when that is the only reason for treatment.

Which one causes less bleeding?

No reliable comparison exists. The two labels report bleeding using different measurements from different trials, and those numbers can't be compared. Bleeding or spotting can occur with either.

Which one causes less weight gain?

No trial has compared them for this. Weight increase and fluid retention appear in Bijuva's post-approval reports; weight increase appears among the reasons women discontinued Angeliq in trials. Neither supports ranking one against the other.

Can I take either one if I've had a hysterectomy?

Both are indicated for women with a uterus. Without a uterus, the second hormone's main purpose usually doesn't apply, which changes the conversation entirely.

Is there a generic for Angeliq?

The FDA approved Novast's 0.5 mg/1 mg drospirenone/estradiol generic on 28 October 2025. We did not confirm a commercial launch, pharmacy stock, or price. The lower 0.25 mg/0.5 mg strength was not identified in that application.

Is there a generic for Bijuva?

The FDA approved Amneal's 1 mg/100 mg estradiol/progesterone generic on 16 May 2022 — but a patent settlement licenses its launch from 25 May 2032. That approval does not cover Bijuva's 0.5 mg/100 mg strength.

Which one is cheaper?

It depends on pharmacy, ZIP code, strength, quantity, coupon, and insurance. At retail Angeliq costs less; with the right discount card Bijuva dropped to a lower per-day cost in our July 2026 check. Check both cards for both drugs before assuming.

Can I switch directly from one to the other?

Not on your own. Your prescriber decides the timing and dose. There's no conversion chart, because they use different second hormones and differ in several other ways at once.

How long before either one starts working?

Both product trials assessed improvement at week 4 and week 12. Follow your prescriber's planned reassessment schedule, and contact them sooner for concerning symptoms, significant side effects, or bleeding that needs evaluation.

Can I take Angeliq if I use ibuprofen regularly?

That's a question for your prescriber or pharmacist, not one to answer yourself. Angeliq's label flags NSAIDs among medicines that can raise potassium and calls for caution and possible monitoring. Don't stop a prescribed medicine to make Angeliq fit — bring the list and let them sort it.

So which one should you ask about?

There is no winner here. There's a fork.

And if you've been putting this off because the warnings frightened you: that fear was reasonable, and part of it was built on a label the FDA has since rewritten. You're allowed to go back and ask again.

The HRT Index is the independent decision resource for online menopause and HRT care. This page is editorial research and was not medically reviewed by a clinician. It is educational only and is not medical advice. Always talk to a qualified clinician before starting, stopping, or switching hormone therapy. Some links on this page are sponsored — we may earn a commission if you use them, at no cost to you, and it never changes what we publish. See our affiliate disclosure, editorial standards, and corrections policy.

Last verified: July 2026. Primary sources: Bijuva prescribing information (DailyMed set ID bc52489a-5149-411d-9665-2c75405ad15d, revised 4/2026); Angeliq prescribing information (DailyMed set ID 761834c2-6b61-4583-84c2-f1ca4a97c4f2, revised 12/2023); FDA menopausal hormone therapy labeling announcements; FDA First Generic Drug Approvals (2022, 2025); Mayne Pharma Bijuva Patient Savings Program card; GoodRx; Drugs.com; bijuva.com; Fournier et al., Int J Cancer (E3N-EPIC cohort); Asi et al., Systematic Reviews; White et al., Circulation 2005;112:1979–84; PROBES trial protocol; joint statement of the BMS, IMS, EMAS, RCOG and AMS.